Third Rock Pumps $41 Million Into Global Blood Therapeutics
This article was originally published in The Pink Sheet Daily
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.
You may also be interested in...
The two biotechs will team up to develop a preclinical oncology asset that could reach human testing as early as next year. The deal is one of many for the Colorado-based biopharma.
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.